Thomas Martin Fay, MD | |
174 Pleasant St, Attleboro, MA 02703-2441 | |
(508) 226-1809 | |
Not Available |
Full Name | Thomas Martin Fay |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 174 Pleasant St, Attleboro, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972838985 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 32847 (Massachusetts) | Primary |
Mailing Address | Practice Location Address |
---|---|
Thomas Martin Fay, MD 174 Pleasant St, Attleboro, MA 02703-2441 Ph: (508) 226-1809 | Thomas Martin Fay, MD 174 Pleasant St, Attleboro, MA 02703-2441 Ph: (508) 226-1809 |
News Archive
Scientists at the National Physical Laboratory (NPL) have mimicked the ways viruses infect human cells and deliver their genetic material. The research hopes to apply the approach to gene therapy - a therapeutic strategy to correct defective genes such as those that cause cancer.
Findings from a UK-led international trial, funded by the Medical Research Council, confirm that premature babies across Europe are being delivered at the right time to save their lives, but preventing brain damage by optimising delivery time is still a challenge.
The Alberta Pharmacists' Association (RxA) and the Canadian Association of Chain Drug Stores (CACDS) stated that they strongly support the new pharmacy funding and services model agreement announced today by Alberta Health and Wellness (AHW).
In a novel research study to begin this week at the Abramson Cancer Center of the University of Pennsylvania, Kathryn Schmitz, PhD, MPH, Assistant Professor in Epidemiology, will help to determine the extent to which a slowly progressive program of strength-training exercises is safe for breast cancer survivors with and without symptoms of lymphedema.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
› Verified 4 days ago
Peter Martin Fay, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 174 Pleasant St, Attleboro, MA 02703 Phone: 508-226-1809 Fax: 508-226-4228 | |
Ellen J Dehm, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 160 Pleasant St, Attleboro, MA 02703 Phone: 508-226-3330 Fax: 508-226-6200 | |
Dr. Frank E Masci, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 160 Pleasant Street, Attleboro, MA 02703 Phone: 508-226-3330 Fax: 508-226-6200 |